Alitretinoin, a vitamin A related compound, is indicated for the topical treatment of AIDS-related Kaposi’s skin cancer. Alitretinoin is an endogenous retinoid that binds to and activates intracellular retinoid receptor subtypes (RAR alpha, RAR beta, RAR gamma, RXR alpha, RXR beta, and RXR gamma), which modulates transcription and expression of genes that control the process of cellular differentiation and proliferation in both normal and cancerous cells. Alitretinoin inhibits the growth of Kaposi's skin cancer cells in vitro.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Alitretinoin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.